The CHEC-SC Cohort Study: CHaractErizing CFTR Modulated Changes in Sweat Chloride and their Association with Clinical Outcomes (the CHEC-SC study)

C
Clement Ren, MD

Primary Investigator

Overview

This study will collect contemporary sweat chloride values from cystic fibrosis patients prescribed and currently receiving commercially approved CFTR modulator therapies.

Description

This is a multicenter, cross-sectional, cohort study which will collect contemporary SC values from approximately 1000 CF patients prescribed and currently receiving commercially approved CFTR modulator therapies.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    cystic fibrosis
  • Age: Between 1 Years - 100 Years
  • Gender: All

Inclusion Criteria
Documentation of a CF diagnosis
Current treatment with a prescribed commercially approved CFTR modulator for at least 3 months prior to enrollment
Exclusion Criteria
Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data
Currently enrolled in an investigational trial (including open-label follow-on studies and EAPs) of an agent expected to have an impact on sweat chloride


Additional Information:
Participants will not be paid for their participation.

Updated on 09 Mar 2024. Study ID: 1712442067

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center